| Title |
Profile of nimotuzumab in the treatment of high-grade glioma
|
|---|---|
| Published in |
OncoTargets and therapy, April 2015
|
| DOI | 10.2147/ott.s60032 |
| Pubmed ID | |
| Authors |
Qun-ying Yang, Cheng-cheng Guo, Zhong-ping Chen |
| Abstract |
High-grade gliomas (HGG) are extremely aggressive lesions and represent the most common primary malignant brain tumors without an effective therapy. Standard treatment for HGG usually includes surgery followed by radiotherapy and chemotherapy. However, the prognosis of patients with HGG remains dismal. We review the humanized epidermal growth factor receptor (EGFR) and the major EGFR target drugs in HGG treatments, focusing on the EGFR antibody nimotuzumab as a new therapeutic strategy in HGG. We found that nimotuzumab with or without radiotherapy, chemotherapy in newly diagnosed or recurrent HGG, such as glioblastoma multiforme (GBM), anaplastic astrocytomas (AA), and diffuse intrinsic pontine glioma (DIPG), might improve the response rate or the survival time. In conclusion, nimotuzumab is a very well-tolerated drug with acceptable toxicity, and it may have promising value in the combination treatment. As a result, multiple center randomized controlled Phase III clinical trials need to be conducted to confirm the efficacy and toxicity for nimotuzumab in HGG. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 33% |
| United States | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 33% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 3% |
| Netherlands | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 56 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 22% |
| Student > Ph. D. Student | 10 | 17% |
| Other | 6 | 10% |
| Student > Bachelor | 5 | 8% |
| Student > Postgraduate | 5 | 8% |
| Other | 10 | 17% |
| Unknown | 11 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 37% |
| Biochemistry, Genetics and Molecular Biology | 5 | 8% |
| Agricultural and Biological Sciences | 5 | 8% |
| Neuroscience | 4 | 7% |
| Immunology and Microbiology | 4 | 7% |
| Other | 7 | 12% |
| Unknown | 13 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2017.
All research outputs
#14,600,553
of 25,374,647 outputs
Outputs from OncoTargets and therapy
#720
of 3,016 outputs
Outputs of similar age
#132,372
of 279,170 outputs
Outputs of similar age from OncoTargets and therapy
#14
of 37 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,170 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.